BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

QDX and Prelude Therapeutics Join Forces to Target Previously Undrugged Oncology Targets

QDX, a computational drug discovery company, announced a collaboration with Prelude Therapeutics, a clinical-stage precision oncology company, targeti...

July 23, 2024 | News

Mabwell's Novel Nectin-4 ADC Approved for Phase II Clinical Trial in Treating Triple-Negative Breast Cancer

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821)...

July 16, 2024 | News

Everest Medicines Announces Positive Topline Data from Phase 3 Trial of Etrasimod for Ulcerative Colitis in Asia

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

July 16, 2024 | News

BioGeometry and Sanyou Bio Forge Strategic Partnership to Innovate Antibody Drug Discovery

BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that spe...

July 12, 2024 | News

Eisai and Biogen Announce Approval of LEQEMBI® (Lecanemab) for Alzheimer’s Disease Treatment in Hong Kong

LEQEMBI is now available for patients with mild cognitive impairment (MCI) or mild dementia, collectively referred to as early AD, the population in which ...

July 11, 2024 | News

DP Technology Nominates DPT0416 as Preclinical Candidate for Alzheimer’s Disease Treatment

DP Technology, an "AI for Science" paradigm-driven company, announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-P...

July 10, 2024 | News

A*STAR and SingHealth Collaborate on SGD$18 Million TISHUMAP Project to Transform Drug Discovery in Asia

A*STAR’s Genome Institute of Singapore (GIS) has secured nearly SGD$18 million to develop an innovative data platform, TISHUMAP1. This platform is se...

July 09, 2024 | News

XPOVIO® Secures NMPA Approval for Treatment of R/R DLBCL in China, Expanding Its Indications

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...

July 08, 2024 | News

South Korea's Genexine Merges with EPD Biotherapeutics to Enhance PROTAC Technology and Drug Pipeline

Genexine a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the tre...

July 05, 2024 | News

Eleva's Factor H Receives Orphan Drug Designation from European Commission for Treating C3 Glomerulopathy

Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today that the European Commis...

July 04, 2024 | News

South Korea's PharmAbcine Advances Novel nAMD Treatment PMC-403 to Key Phase 1 Milestones

PharmAbcine, a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance ...

July 02, 2024 | News

European Commission Approves OBGEMSA™ (Vibegron) for Overactive Bladder Treatment by Pierre Fabre Laboratories

The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overac...

July 01, 2024 | News

Cytiva Introduces Supor Prime Filters to Enhance High-Concentration Biologic Drug Manufacturing

Global life sciences leader Cytiva is addressing the distinct filtration needs of customers manufacturing high-concentration biologic drugs with its Supor ...

June 28, 2024 | News

South Korea Approves Reimbursement for Antengene's XPOVIO®, Expanding Access to Relapsed/Refractory Multiple Myeloma Treatment

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...

June 27, 2024 | News

Stay Connected